

**UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE**

VALERIE MONTGOMERY RICE, M.D.

**DEPARTMENT OF OBSTETRICS AND
GYNECOLOGY**

Office Address:

University of Kansas Medical Center
Department of Obstetrics and Gynecology
Division of Reproductive Endocrinology
3901 Rainbow Boulevard
Kansas City, Kansas 66160-7316

Date of Birth: _____
Place of Birth: _____
Current Citizenship: _____
Social Security#: _____

PROFESSIONAL REGISTRATION/LICENSURE:

_____	1993	Kansas
_____	1997	Michigan
_____	1988	Georgia
_____	2000	Missouri

EDUCATION:

1983	B.S., Chemistry, Georgia Institute of Technology; Atlanta, Georgia.
1987	M.D., Harvard Medical School; Boston, Massachusetts

POSTGRADUATE EDUCATION:

1987-1988	Internship: Department of Gynecology and Obstetrics, Emory University School of Medicine & Affiliated Hospitals; Atlanta, Georgia
1988-1991	Residency: Department of Gynecology and Obstetrics, Emory University School of Medicine & Affiliated Hospitals; Atlanta, Georgia
1991-1993	Fellowship: Reproductive Endocrinology and Infertility, Hutzel Hospital; Detroit, Michigan
2000	AAMC Professional Development Seminar for Senior Women in Medicine, Baltimore, Maryland

FACULTY APPOINTMENTS:

1991 - 1993	Clinical Instructor, Wayne State University
1993-July 1997	Assistant Professor, University of Kansas School of Medicine, Department of Obstetrics and Gynecology
1996-July 1997	Vice Chairman, Department of Obstetrics and Gynecology, University of Kansas, School of Medicine
1996-July 1997	Medical Director, Clinical Trials Division, Clinical Research Institute of the University of Kansas School of Medicine
1997-June 1998	Senior Staff Physician, Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology Henry Ford Medical Center, Troy, Michigan
July 1998 - Present	Associate Professor (Tenured), University of Kansas Medical Center, Department of Obstetrics and Gynecology and Director, Division of Reproductive Endocrinology and Infertility

BOARD CERTIFICATION:

1988	Diplomate-National Board Medical Examiners
1994	Board Certified-American College of Obstetrics & Gynecology
1997	Board Certified for Subspecialty in Reproductive Endocrinology

PROFESSIONAL SOCIETIES (Previous/Current):

1983	Aesculapian Club of Harvard Medical School
1983	American Medical Association
1988	Fellow-American College of Obstetrics and Gynecology
1991	American Society of Reproductive Medicine (formerly American Fertility Society)
1992	American Medical Women's Association
1994	Kansas City Gynecological Society
1994	Kansas City Medical Society
1994	Clay-Platte County Medical Society
1994	National Medical Association
1995	Kaw Valley Medical Society
2000 – 2001	Nominating Committee for the Society of Reproductive Endocrinology & Infertility (<i>An Affiliate of the American Society of Reproductive Medicine</i>)
2000	North American Menopause Society (NAMS)
2002	Scientific Committee (NAMS)

FELLOWSHIPS:

1986-1987	Commonwealth Fund Medical Fellowship; National Medical Fellowship; — award
1991-1992	ACOG/Ethicon Research Award for Innovations in Gynecologic Surgery — award

HONORS AND AWARDS:

1987	Poster Presenter at the Soma Weiss Research Assembly, Harvard Medical School
1989	Recipient of John D. Thompson Resident Research Day First Place Award
1991	Recipient of John D. Thompson Resident Research Day First Place Award
1990	Recipient of Second Place Oral Presentation Award and Second Place Poster Award at
1991	ACOG IV District Meeting
1991	Recipient of DeKalb County Medical Society Resident Research Award
1991	Recipient of Milford B. Hatcher, M.D. Resident Research Award for the State of Georgia
1993	Fellow Research Award, Second Place Award, Hutzel Hospital; Wayne State University
1998	Outstanding Faculty Teaching Award, Henry Ford Hospital System, Department of Obstetrics and Gynecology, Detroit, Michigan
2000	Elected to expert panel of Board Certified Specialists for CIGNA HealthCare of Kansas/Missouri
1999	Elected to The Society of Reproductive Endocrinology and Infertility, Inc. (SREI) Nominating Committee
2001	Appointed to Missouri Life Sciences Committee by Governor Bob Holden

LEADERSHIP & OTHER HONORS:

1987 Inducted into Aesculapian Club of Harvard Medical School
2002 Co-Director, Faculty Development, Center of Excellence, University of Kansas School of Medicine

ORGANIZATIONS

Advisor, Students for Women's Wellness

Served on the Planning Committee and as Faculty Member for the GYN Diverse Surgeon Initiative, August 13, 2000 during the National Medical Association Meetings in Washington, DC.

RESEARCH ACTIVITIES:

Research Interests and Current Projects Underway:

1. Use of Purified Hormones to Induce Ovulation
2. Postoperative Adhesion Prevention
3. Role of Tumor Necrosis Factor in Ovarian Steroidogenesis
4. Role of Gonadotropins in Ovarian Cancer

GRANTS:

1993-1994 Mediventures - _____ for Study to Determine the Amount of Poloxamer 407 (Flowgel) Needed for Adhesion Prevention

1994 - Present Upjohn - Principal Investigator. _____ for Assessment of Bone Mineral Density in Women Receiving Depo-Provera Contraceptive Injections

1994-1997 Wyeth Ayerst, Principal Investigator- _____ Assessment of lower doses, of Premarin in Postmenopausal Women on HRT

1994-1998 National Institute of Health/National Cancer Institute - Minority Supplement - \$174,000 (direct cost); "Ovarian Tumor Necrosis Factor" The effect of TNF alpha on human granulosa and theca cells

1996-1997 Wyeth Ayerst, Principal Investigator - _____, substudy: Health & Osteoporosis, Progestin and Estrogen Study

1996-1997 Wyeth Ayerst, Principal Investigator, _____, Levonorgestrel & EE

1997-1998 Ethical, Principal Investigator- _____: Continuous Estrogen/Progestin Hormonal Replacement Patch (HRT)

1997-1998 Wyeth Ayerst, Principal Investigator- _____: Pilot Study to evaluate Parameters of Four Trimegestone/Ethinyl Estradiol Oral Contraceptive Regimens and Estrostep

1997-1998 Wyeth Ayerst, Principal Investigator- \$ _____ Vasomotor HRT Patch Study

1998 Serono Laboratories, Principal Investigator- \$ _____ Multicenter Trial to Assess the Safety and Efficacy of Gonal F-versus Fertinex for the Induction of Multiple Follicular Development in Infertile Couples Undergoing ART,

1999 - Present Parke-Davis - Open Label Study Comparing Breakthrough Bleeding Profiles or women on a Study Drug, Principal Investigator, _____

2000 - Present Wyeth-Ayerst, Principal Investigator, Prospective Study of Effects of Premarin Vaginal Cream and Low Dose Premarin/MPA in Sexual Function, _____

- 2000 - Present Serono – Prospective, Randomized, Comparative Single Center Trial to Compare the Safety and Efficacy of Gonal-F and Lupron administered as single and separate injection (Product)
- 2002 - Present Wyeth-Ayerst, Principal Investigator, Assess safety and efficacy of TSE-424 to Decrease the Incidence of Fracture Risk in Postmenopausal Women with Osteoporosis, _____
- 2001 Serono Laboratories, Phase 3 comparative trial of a new formulation of f-hRSH, Principal investigator, _____
- 2001 NIH, NCI, Ovarian Tumor Necrosis Factor, 7/1/99-11/30/04, \$997,402 (direct costs only) includes **Minority Investigator Supplement for Valerie Montgomery Rice, M.D.**, 40% effort, Associate Professor, Obstetrics & Gynecology, University of Kansas School of Medicine; 3/1/00-12/31/04, \$219,599; Principal investigator- _____
- 2001 NIH, NICHD, Center for Reproductive Sciences, 4/01/01-3/31/06, \$3,574,651 (direct costs); Project II, Src Kinase and Ovarian Function; Direct Costs \$733,485; Co-investigator 5% effort; Co-investigator-**Valerie Montgomery Rice, M.D.**, Principal investigator, _____
- 2001 Organon, Assess the endometrial histological profile treatment with tibolone (OrgOD14) vs. CE plus MPA in postmenopausal women, _____
- 2002 Wyeth-Ayerst, Principal Investigator, Assess Safety and Efficacy of TSE-424 in the Prevention of postmenopausal osteoporosis, _____
- 2002 Pfizer, Assessing the Effects of Femhrt on vasomotor symptoms in postmenopausal women of minority ethnic groups, _____
- 2002 Wyeth, A Double-blind, Randomized, Placebo-and Active Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women. _____
- 2002 Ethicon, Minimally Invasive Surgery Training Grant, Project Director, _____

CLINICAL ACTIVITIES (current):

Clinic Time - inoffice patients	37.5%
Surgery patients	37.5%

TEACHING EXPERIENCE:

- 1991-1993 OHEP-Wayne State University-Continuing Medical Education Instructor of Laser Endoscopy Course
- 1991-1993 Wayne State University School of Medicine Year III Medical Students-One Lecture/rotation (every six weeks)
- 1994 Course Director: Hysteroscopy and Endoscopy: Current Applications, University of Kansas Medical Center (December 10, 1994)
- 1996 Course Director: Current Issues and New Techniques in Gynecology, Ritz-Carlton, Kansas City, Kansas (August 2-3, 1996)
- 1996 Course Director: Current Trends in Advanced Laparoscopy, University of Kansas Medical Center (August 27, 1996)
- 1997 Course Director: Management of Women with Benign Gynecologic Conditions, Ritz-Carlton, St. Louis, Missouri (June 13, 1997)
- 1998 Trainer for Gynecare – ThermoChoice and Versapoint
- 1998 Course Director: Challenges in Gynecologic Care, Ritz-Carlton, Dearborn, Michigan (April 17, 1998)
- 1998 - Present Medical Student Lecture on “Menopause” – four times/year
- 1999-Present First year medical students regarding pelvic anatomy for the Human Anatomy and Embryology (Gross) course (Annual)
- 1999-Present Assisted Reproductive Technologies to first year medical students in Cell and Tissue Biology course (Annual)
- 2000 - 2001 Course Director for Hands-on Laparoscopic Training Course for Gynecologic Surgeons, National Medical Association and Ethicon Endo Surgery (August 2000, November 2000, March 2001)

- 2000 Diversity in Menopause; Session Chair, NMA Annual Convention, Nashville, TN
2001 - Present Faculty Presenter, Health, Hormones, Happiness, Johns Hopkins Medical Center
2002 Faculty, Comprehensive Update in Gynecology & Obstetrics, Emory University Postgraduate Course, Amelia Island, FL
2002 Course Director: Managing the 21st Century Woman, University of Kansas Medical Center (March 1-2, 2002)
2002 Faculty, ACOG Advisory Board for REI Prolog

COMMITTEES:

- 1984 - 1985 Admissions Committee Member, Harvard Medical School
1993 International Exchange Committee, University of Kansas Medical Center
1993-1994 Operating Room Committee, University of Kansas Medical Center
1993-1994 Search Committee for Associate Dean of Research, University of Kansas Medical Center
1993-1994 Anesthesiology Chair Search Committee, University of Kansas Medical Center
1994-1997 Space Allocation Advisory Committee, University of Kansas Medical Center
1996-1997 Internal Advisory Cancer Committee for Cancer Center, University of Kansas
1998 - Present Executive Committee, Department of Obstetrics and Gynecology, University of Kansas Medical Center
1995 - Present Education Committee, Department of Obstetrics and Gynecology, University of Kansas Medical Center
1999 - Present Human Subjects Committee, University of Kansas Medical Center
1999 Cooperative Reproductive Medicine National Study Section, NIH
2000 Served on Pharmacology Chair Review Committee
2000 - Present Advisory Committee for Md/PhD Program
2001 - Present Member of Population Research Study Section - NIH
2001 - Present Academic Committee, School of Medicine, University of Kansas Medical Center
2001 - Present Admission Committee, School of Medicine, University of Kansas Medical Center
2001 - Present State of Missouri Life Sciences Committee
2001 - Present Scientific Committee for The North American Menopause Society
2002 - Present Advisory Committee for FDA, Division of Reproductive and Neurologic Drugs

ORAL/INVITED PRESENTATIONS:

1. Fibrinolytic parameters in follicular fluid. American Fertility Society, 49th Annual Meeting, Montreal, Canada, 1993.
2. Ovulation induction protocols and assisted reproductive technologies. Kansas City Gynecological Society Meeting, January, 1994.
3. Histopathologic changes in rat peritoneum after injury and treatment with Interceed and Poloxamer 407. Poster presentation. The American College of Obstetricians and Gynecologists, 42nd Annual Clinical Meeting, Orlando, FL., May, 1994.
4. Coagulation and fibrinolytic processes in habitual abortion. National Medical Association meeting, San Antonio, Texas, July, 1994.
5. Impact of infertility on the Black community. Second Midwest Regional Conference on Black Families and Children, Kansas City, Kansas, August, 1994.
6. Medical versus Surgical Treatment for Endometriosis. University of Kansas, Operative Hysteroscopy Course, October, 1994.
7. Medical versus Surgical Treatment for Endometriosis. National Medical Association, Atlanta Ga., July 1995.
8. The Effects of HRT on Cardiovascular Disease. Grand Rounds, Shawnee Mission Medical Center, August 1995

9. Barrier Adjuvants for the Prevention of Post-operative Adhesion Formation. The American Fertility Society, 51st Annual Meeting, Seattle, Washington, 1995.
10. Endometriosis: Diagnosis and Treatment. Fortis Insurance Company, Kansas City KS, February 1996.
11. Uterine Fibroid Disease, National Medical Association, Chicago, Illinois, July 1996.
12. Academic Medicine and You. Health Science Enrichment Institute, University of Kansas Medical Center, July 1996
13. The Targeted Cost-Effective Infertility Evaluation, Current Issues and New Techniques in Gynecology, Kansas City, MO, August 1996.
14. Postoperative Adhesion Prevention, Current Issues and New Techniques in Gynecology, Kansas City, MO, August 1996.
15. Failure of Ovarian Suppression to Reduce Postoperative Adhesion Development in Women; Seprafilm Adhesion Study Group, American Society for Reproductive Medicine, Boston, Mass., November, 1996.
16. Medical and Surgical Treatment of Uterine Fibroids, Management of Women with Benign Gynecologic Conditions, St. Louis MO, June 1997.
17. Long term use of GnRH Agonist, Management of Women with Benign Gynecologic Conditions, St. Louis MO, June 1997.
18. How to Practice Evidence Based Medicine, Management of Women with Benign Gynecologic Conditions, St. Louis, MO, June 1997.
19. Hormone Replacement Therapy: Insights on Women's Health, Women's Foundation of Greater Kansas City, Johnson County Community College, Overland Park, Kansas, June 12, 1997.
20. Postoperative Adhesion Prevention, Cost-Effective Managed Care for the Patient with Endometriosis or Uterine Fibroids, Atlanta, GA, September 1997.
21. Evidence Based Medicine, Cost-Effective Managed Care for the Patient with Endometriosis or Uterine Fibroids, Atlanta, GA, September, 1997.
22. Management of Dysfunctional Uterine Bleeding, ASRM Roundtable, Cincinnati, Ohio, October 1997.
23. Effect of Consecutive Ejaculation on the Total Number of Motile Sperm Inseminated. 53rd Annual Meeting of The American Society for Reproductive Medicine, Cincinnati, Ohio, October 1997.
24. Contraception. 7th Annual ASRM Resident Reporter Program, 53rd Annual Meeting of The American Society for Reproductive Medicine, Cincinnati, Ohio, October 1997.
25. Evidence Based Medicine, Management of Women with Benign Gynecologic Conditions, Learning to Factor Costs and Effectiveness in Making Treatment Decisions, New Orleans LA, November, 1997.
26. An Overview of the Pathophysiology of Endometriosis, Management of Women with Benign Gynecologic Conditions, Learning to Factor Costs and Effectiveness in Making Treatment Decisions, New Orleans LA, November, 1997.
27. Controversies in Hormone Replacement Therapy, Grand Rounds Henry Ford Medical Center, Troy, MI, February 1998.

28. The development of Low dose OCP's. Grand Rounds, Michigan State University School of Medicine, Lansing MI, March 1998.
29. Evidence-Based Medicine: Integrating It into Your Practice, Challenges in Gynecologic Care, Dearborn, MI, April 1998.
30. Management of Laparoscopically Confirmed Endometriosis, Challenges in Gynecologic Care, Dearborn, MI, April 1998.
31. Pre-Menstrual Syndrome, Community Outreach Program, Detroit, MI, April 1998.
32. Menopause, National Medical Association, Detroit, MI, April 1998.
33. Patient Management Decision in Hormone Replacement Therapy, American Heart Association, Dallas, TX, April 1998.
34. Technology and Information Updates, Challenges in Gynecologic Care, Dearborn, MI, April 1998.
35. Understanding PMS, Menopause, Mood Swings, Depression, and Osteoporosis, Women's Health Matters: An Evening of Preventive Healthcare Discussions, St. Louis, MO, May 1998.
36. Contraception in the 90's, 11th Annual ACOG Meeting, New Orleans, LA, May 1998.
37. Trends in Gynecology for the Next Millennium: "Controversies in Hormone Replacement Therapy", "The Nuts and Bolts of the Infertility Evaluation", "Postoperative Adhesion Prevention: What Really Works?", "Tracking Outcomes and Practice Evidence-Based Medicine", Atlanta, GA, August 1998.
38. Infertility Treatment: Dilemmas & Controversies for the Neonatal Critical Care Update 1998 at Overland Park Regional Medical Center, Overland Park, KS, October 16, 1998.
39. New Directions in the Management of the Female Patient: 4th Annual OB/GYN Faculty Update for TAP Pharmaceuticals and Medical Education Collaborative, Scottsdale, AZ, January 15-16, 1999.
40. Estrogen and Breast Cancer for the Missouri Society of American College of Osteopathic Family Physicians, Kansas City, MO, January 22, 1999.
41. Revolution or Retreat: Women's Healthcare in the Next Millennium, San Juan, Puerto, Rico, February 4-7, 1999.
42. The Influence of Culture in the Practice of Medicine as part of "Our Black History Month Celebration" for the KUMC Branch of the Student National Medical Association, February 12, 1999.
43. ERT/HRT – Approaches/Benefits in Hormone Replacement Therapy, Springfield, MO, February 23, 1999. Long-Term Consequence of Menopause as part of "Time for Ourselves: A health event for the mature woman" Phoenix, AZ, March 20, 1999.
44. "Hints from Heloise, A Women's Heart Health Event" and Ask the Doctor Round Table Discussion for the American Heart Association, St. Louis, MO, March 30, 1999.
45. KUMC, Urology Resident Conference on "Infertility", April 30, 1999.
46. Keynote Speaker at Women's Health Symposium, "Status of Women's Health", Kansas City, MO, May 14, 1999.

47. "Grand Rounds" for Jeff City Medical Group "OC and HRT" Jefferson City, MO, September 16, 1999.
48. "Hormones in the 30' and 40's – Perimenopause" and "Hormones in the 50's and 60's – Menopause" for Women's Health Conference, September 25, 1999.
49. "Latest in IVF and ICSI" as part of the Family Building Fair sponsored by RESOLVE of Kansas City, October 16, 1999.
50. "Prevention of Postmenopausal Osteoporosis: Debating the Issues", Southern Medical Association, 93rd Annual Scientific Assembly, Dallas, TX, November 11, 1999
51. Guest Lecturer , "Menopause Recognition and Treatment Decisions", University of Health Sciences College of Osteopathic Medicine, Kansas City, MO, 1999
52. "Health Care Issues for the Mature Woman: Does Race Matter?", Central Exchange, Kansas City, MO, February 29, 2000.
53. Grand Rounds "Management of Women with Chronic Pelvic Pain and Endometriosis", Department of Obstetrics and Gynecology Grand Rounds, UMKC, Kansas City, MO, March 10, 2000.
54. "Hormones Throughout Life", Hallmark Cards, Kansas City, MO, May 25, 2000
55. Recombinant human follicle stimulating hormone (r-FSH, Gonal-F®) and leuprolide acetate (LA, Lupron®) administered in single or separate injections in women undergoing *in vitro* fertilization (IVF): Preliminary results. European Society of Reproductive Endocrinology, Bologna, Italy, June 2000
56. "ART: It's More than Sperm and Eggs", Kaiser Permanente, Kansas City, MO, August 9, 2000
57. "Endometriosis – Laparoscopic: Recognition and Surgical Management", National Medical Association, Washington, DC, August 13, 2000
58. "Health-care Issues for the Mature Woman – Does Race Matter", National Medical Association, Washington, DC, August 16, 2000
59. Speaking of Women's Health, "Menopause, Women of Color, and Hormone Replacement Therapy", Kansas City, MO, September 9, 2000
60. Quality of Life Issues, "Vasomotor Symptoms: Lifestyle Consequences", CMES Ancillary Symposium, Philadelphia, PA, October 3, 2000
61. "Emerging Directions in Menopause Management – Lowering HRT Doses", ASRM, San Diego, CA, October 21-26, 2000
62. GYN DIVERSE SURGEON INITIATIVE – Advanced Laparoscopic Course, Laparoscopic Assisted Vaginal Hysterectomy, Myomectomy/Morecellator, Pre-Sacral Neuroectomy, Cincinnati, OH, November 6-7, 2000
63. "Menopause and Hormone Replacement Therapy", Southminster Presbyterian Church, Prairie Village, KS, November 19, 2000
64. Annual Winter Seminar in the Missouri Osteopathic, "Menopause", Kansas City, MO, January 25, 2001
65. "Effects of fertility drugs as they interact with other medications – prescribed such as for high blood pressure or diabetes and over-the-counter such as Tylenol". RESOLVE, Overland Park, KS, February 21, 2001

66. "Optimizing Women's Health During Menopause", Total Therapeutic Management, Overland Park, KS, April 7, 2001
67. "Endometriosis: Emerging Research and Intervention Strategies", NICHD Workshop, Bethesda, MD, April 9, 2001
68. "New Strategies in Menopausal Health: Lowering HRT Doses", Washington, DC, May 5, 2001
69. "Menopause" – 9th Annual Congress on Women's Health, Washington, DC, June 4, 2001
70. "Women and Heart Health" – St. Luke's Hospital, Kansas City, MO, June 21, 2001
71. "Hormone Replacement Therapy", Family Medicine Association, St. Joseph, MO, July 20, 2001
72. "Health, Hormones, and Hot Flashes", Hallmark Inc. – Kansas City, MO, July 24, 2001
73. "Diversity in Menopause", Session Chair - NMA Annual Convention and Scientific Assembly, Nashville, TN, August 4, 2001
74. Update on HRT" – Pri-Med Update Meeting, Cincinnati, OH, September 7, 2001
75. Speaking of Women's Health, Kansas City, MO, September 8, 2001
76. Women of Cancer, Breast Cancer Prevention and HRT, "Managing Menopause and HRT", Kansas City, MO September 29, 2001
77. "How Does Diversity Influence Menopause and Disease?", Plenary Speaker at the 12th Annual Meeting, The North American Menopause Society, October 4, 2001
78. "Low Dose Hormone Replacement Therapy in the New Millennium", Clinical Endocrine Update Meeting, Chicago, IL, October 9, 2001
79. Faculty member "The 50-Something woman: What We Know; What We think We Know; What We Need to Know", "Care of the Mature Women", 57th Annual ASRM Meeting, Orlando, FL, October 24-25, 2001
80. Session Chair Gynecology Update, "Managing the Menopausal Woman Beyond the 21st Century", Annual Fall Family Clinical Conference, Overland Park, KS, November 2, 2001
81. Rationale for Low Dose Hormone Therapy, World Foundation for Medical Studies in Female Health, New York, NY, December 17, 2001
82. Health, Hormone, Happiness Symposium, Faculty Presenter 2001
83. "Advances in HRT", Turner Syndrome Society, Kansas City, KS, January 12, 2002
84. "Managing Menopause: Making the transition with a Positive Impact on the Quality of Life" and "HRT –Strking a Balance", Turning Points Conference, Dearborn, MI, February 1-2, 2002
85. "Osteoporosis – Prevention and Management Considerations", Live Audio Presentation for University of Wake Forest, Winston-Salem, NC, March 6-7, 2002
86. "Controversies Surrounding HRT", Grand Rounds at the University of Colorado Health Sciences Center, Denver, CO, March 25, 2002
87. "Women's Menopausal Health". Appearance on KPRS Radio Station, Kansas City, MO, April 3, 2002

88. "Optimizing the Dose and Route of HRT", Grand Rounds White Memorial Hospital, "Menopause", Grand Rounds at St. Mary's Hospital, "Impact of Diversity on Menopause", Grand Rounds at King Drew Medical Center, "Controversies in HRT", Grand Rounds at USC and UCLA, Los Angeles, CA, April 10-12, 2002
89. Moderator for AMWA Round Table on HRT, St. Regis Hotel, Los Angeles, CA, April 10, 2002
90. "HRT and Its Impact on Breast Cancer and Cardiovascular Disease", Missouri State Nurse Practitioner Meeting, Jefferson City, MO, April 25, 2002
91. "HRT", Grand Rounds at University of Chicago, Chicago, IL, May 17, 2002
92. "PCO/Hirsutism and Endometriosis: Medical Management", Emory University Post-Graduate Course, Amelia Island, FL, May 28-29, 2002
93. "Impact of Osteoporosis on African American Women". National Black Nurses Association 30th Annual Institute and Conference, Hyatt Regency Houston, Houston, TX, July 25, 2002
94. "Surgical Management of Endometriosis", NMA Annual Meeting, Honolulu, HI, August 3-8, 2002
95. "Controversies in Hormone Replacement Therapy", Minneapolis State ACOG Meeting, Brainerd, MN, August 23, 2002.
96. "Menopause Risks and Benefits", Journey To Wellness Syndicated Radio Talk Show. August 25, 2002

PHYSICAL FACILITIES AVAILABLE:

Office - 3rd Floor Wescoe

Laboratory - 5th Floor KU Hospital

PUBLICATIONS:

1. **Montgomery V, Loutradis D, Tulchinsky D, Kiessling A.** FSH-induced ovulation in intact and hypophysectomized mice. *J Reprod Fert* 84:1-6, 1988.
2. **Montgomery V, Molter H, Mitchell D.** FSH-induced ovulation, results in fertilization and normal pregnancy in the mouse. *Life Sciences* 53(1): 31-39, 1993.
3. **Wiskind A, Montgomery V, Dudley G.** Evaluation of Interceed to prevent post-operative adhesions on the rabbit ovary. *Ostet Gynecol* 81(6): 1025, 1993.
4. **Montgomery Rice V, Shanti A, Moghissi KS, Leach RE:** A comparative evaluation of Poloxamer 407 and oxidized regenerated cellulose (Interceed [TC7]) to reduce postoperative adhesion formation in the rat uterine horn model. *Fertil Steril* 59(4): 901-906, 1993.
5. **Montgomery Rice V, et al:** Fibrinolytic parameters in women undergoing ovulation induction. *Am J Obstet Gynecol* 169(6): 1549-1553, 1993.
6. **Montgomery Rice V, et al:** New options for the diagnosis and treatment of ectopic pregnancy. *Female Patient* 18(5): 31-46, 1993.

7. **Montgomery Rice V**, et al: Tumour Necrosis Factor-Alpha Inhibits Follicle Stimulating Hormone-Induced Granulosa Cell Oestradiol Secretion in the Human: Dependence on Size of Follicle. *Human Reproduction* 11(6): 1256-1261, 1996.
8. Diamond, Michael P: Reduction of adhesions after uterine myomectomy by Seprafilm (HAL-F),* A blinded prospective, randomized, multicenter clinical study. *Fertility & Sterility* 67 (1):13-15, 1997.
9. Terranova, PF Ph.D. and **Montgomery Rice V**, M.D. Review: Cytokine Involvement in Ovarian Processes. *American Journal of Reproductive Immunology* 37:50-63, 1997.
10. **Montgomery Rice V**, Limback D.L., Roby K.F., Terranova P.F.: Changes in Circulating and Ovarian Concentrations of Bioactive TNF-A During the First Ovulation at Puberty in Rats and in Gonadotrophin-treated immature rats. *Journal of Reproduction and Fertility* 113:337-341, 1998.
11. **Montgomery Rice V.**, Limback D.L., Roby K.F., and Terranova P.F.: Differential responses of granulosa cells from small and large follicles to follicle stimulating hormone (FSH) during the menstrual cycle and acyclicity: effects of tumor necrosis factor alpha. *Human Reprod.*, 13(5):1285-1291, 1998.
12. Richard Davis G, **Montgomery Rice V**, et al.: Primary Hemostasis in Controlled Ovarian Hyperstimulation Cycles. *Fertility & Sterility* 67 (5): 923-927, 1998.
13. **Montgomery Rice V**, et al: Tumor Necrosis Factor Inhibits Estradiol Secretion in the Follicular Phase of the Menstrual Cycle, *Human Reproduction* 13(4): 1284-1291, 1998.
14. **Montgomery Rice V**, Limback D.L., Roby K.F., and Terranova, P.F.: Tumor necrosis factor alpha inhibition of follicle stimulating hormone-induced granulosa cell estradiol secretion in the human does not involve reduction of cAMP secretion but inhibition at post cAMP site(s). *Endocrine* 10(1): 19-23, February 1999.
15. Surrey E.S., and the Add-Back Consensus Work Group (**Montgomery Rice V**), Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached?, *Fertility & Sterility*, March 1999;71(3): 420-424.
16. **Montgomery Rice V**. Member of the Pelvic Pain Expert Working Group – Scialli Anthony R., for the Pelvic Pain Expert Working Group: Evaluating Chronic Pelvic Pain: A Consensus Recommendation, *J. Reprod Med* 1999;44:945-952.
17. **Montgomery Rice V**. "Menopause in Managed Care: Clinical Benefits and Risks of Hormone Replacement Therapy – How to help your patients decide what's best for them". *WOMEN'S HEALTH in Primary Care* (Supplement), Vol. 3, No. 9, September 2000.
18. **Montgomery Rice V**. "Emerging Directions in Menopause Management: Lowering HRT Doses". *The Official 2000 Symposium Highlights*, September 2000.
19. **Montgomery Rice V** and Amerongen DV: "Menopause in Managed Care" *Women's Health in Primary Care*, selected presentations from the 5th Annual National Meeting of the IPA Association of America and the 12th Annual National Managed Health Care Congress, December 2000 Supplement.
20. Thomas MA, Kessel B, Miles T, O'Dell MO, **Montgomery Rice V**, et al.: "Strategies to encourage hormone replacement therapy use in minority or diverse populations: A consensus opinion" *Clin J Women's Hlth*, Vol. 1, No. 1, December 2000.
21. **Montgomery Rice, V.**, Chaudry, A., Oluola, O., Limback, S.D., Roby, K.F., and Terranova, P.F. Herbimycin, a Tyrosine Kinase Inhibitor with Src Selectivity, Reduces Human Granulosa Cell Progesterone and Estradiol Secretion, submitted to *Endocrine*, April 2001.

22. Speroff L, Gallagher JC, **Montgomery Rice V**, Pinkerton JV, Raisz LG: Menopause Management: The Impact of Low-Dose HRT. *Contemp OB/GYN* July 2001;47(7)(suppl):3-29.
23. Consensus Working Group: Management of Women with Chronic Pelvic Pain Secondary to Endometriosis: Development of an Evidence Based Consensus Approach. *Fertility and Sterility* December 2001
24. Diamond MP, **Montgomery Rice V**: "Serum Electrolytes, Chemistries and Blood Cell Counts after Gynecologic Surgery in Healthy Woman", *Journal Gynecologic Techniques*, 2000;6(3):99-106.
25. **Montgomery Rice V**, "Hormone Replacement Therapy: Optimising the Dose", *Drugs & Aging*, submitted, Fall 2000, scheduled for publication December 2002
26. **Montgomery Rice V**, "Conventional Medical Therapies for Endometriosis", *The Annals*, New York Academy of Sciences. March 2002;955:343-352.
27. **Montgomery Rice V**, "Optimizing The Dose of Hormone Replacement Therapy", *International Journal of Fertility and Women's Medicine*, Sept/Oct 2002;47, 5:

CHAPTERS:

1. "Ovulation Predictors and Postcoital Testing". *Infertility And Reproductive Medicine Clinics Of North America*, Vol. 6, No. 1, 1995.
2. "Therapeutic donor insemination: screening, indications and technique". *Evaluation and Treatment of the Infertile Male*, Cambridge University Press, 1996.
3. "Hemostasis and Ovulation Induction", *Infertility & Reproductive Medicine Clinics of North America*. Vol. 3, January, 1997
4. "Pre-Operative Evaluation Prior to Myomectomy". Beiber, Martin V, eds. *Myomectomy*. Maiden: Blackwell Science, July 1998.
5. "The Impact of Infertility in the Black Community" as part of the book entitled *Health Care and Empowerment in the Black Community: Knowledge, Skills and Collectivism* The Haworth Press, Inc., Book Division, March 2001.

ABSTRACTS:

1. **Montgomery Rice V**, Wiskind A, Dudley G: Prevention of postoperative adhesion formation using Intercede in the rabbit ovary model. The American College of Obstetricians & Gynecologists, District IV Meeting, North Carolina, 1990.
2. **Montgomery Rice V**, Shanti A, Moghissi KS, Leach RE: Poloxamer 407 but not Interceed reduces adhesion formation in the rat uterine horn model. Society of Gynecological Investigation, San Antonio, TX 1992.
3. **Montgomery Rice V**, Moghissi KS, Leach RE: Effects of Poloxamer 407 and ringers lactate on post-operative adhesion formation in the rat uterine horn model. 2nd International Symposium on Gynecologic Surgery & Adhesion Prevention, Palm Beach, FL 1992.
4. **Montgomery Rice V**, Hirata J, Shanti A, Harold P, Blacker C, Ginsbvurg K, Mammen E, Moghissi K, Leach R: Alteration of the fibrinolytic system in habitual abortion. 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, 1992.

5. Rousseau M, Hagan D, Tipton T, Rice V, Shanti A, Blacker C: Intrauterine insemination (IUI): A retrospective comparison of patient pregnancy rates for physician- and registered nurse (RN)-performed procedures. 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, 1992.
6. Shanti A, **Montgomery Rice V**, Moghissi K, Leach R: The effect of Interceed and Poloxamer 407 on adhesion formation in a rabbit ovarian model. 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, 1992.
7. Shanti A, **Montgomery Rice V**, Ramirez N: Re-epithelization of the rabbit's ovary: Histological Interceed and Poloxamer 407. Society of Gynecological Investigation, Toronto, Canada, 1993.
8. **Montgomery Rice V**, Richard-Davis G, Hirokawa S, Saleh A, Blacker C, Ginsburg K, Mammen E, Moghissi K, Leach R: Fibrinolytic parameters in women undergoing ovulation induction. Society for Gynecological Investigation, Toronto, Canada, 1993.
9. **Montgomery Rice V**, Ramirez, N: Use of rabbit model for evaluation of curettage induced endometrial damage and effects of poloxamer 407 in reducing scar tissue formation. XV European Congress of Pathology, Copenhagen, Denmark. September, 1995. *Pathol Res Pract* 191:785; 1995.
10. Diamond, Michael P, **Montgomery Rice V**: Reduction of adhesions after uterine myomectomy by Seprafilm (HAL-F),* A blinded prospective, randomized, multicenter clinical study. European Society for Gynecological Endoscopy in Brussels, December 1995.
11. **Montgomery Rice V**, Limback S, Roby K, Terranova P: Evidence for hormonally regulated changes in ovarian and circulating levels of bioactive tumor necrosis factor alpha in the gonadotropin-treated immature rat. Society of Gynecological Investigation, Philadelphia PA, 1996.
12. **Montgomery Rice V**, Williams V, Limback S, Terranova P: Tumor necrosis factor alpha inhibits follicle stimulating hormone-induced granulosa cell estradiol secretion in the human: Dependence on stage of follicular development. Society of Gynecological Investigation, Philadelphia PA, 1996.
13. **Montgomery Rice V**, Limback S, Terranova P: Differential Steroidogenic Responses of Follicles to Tumor Necrosis Factor Alpha in Follicular and Luteal Phases of the Menstrual Cycle. 53rd Annual Meeting of The American Society for Reproductive Medicine, Cincinnati, Ohio, 1997.
14. Brown, S, **Montgomery Rice V**, *et al.*: Effect of Consecutive Ejaculation on the Total Number of Motile Sperm Inseminated. 53rd Annual Meeting of The American Society for Reproductive Medicine, Cincinnati, Ohio, 1997.
15. Ring S, Tawfik O, Terranova P, **Montgomery Rice V**, *et al.*: Immunological localization of tumor necrosis factor-alpha in the human ovary. *Society of Gynecological Investigation*, 1999.
16. Silverberg KM, **Montgomery Rice V**, *et al.*: Recombinant human follicle stimulating hormone (r-FSH, Gonal-F®) and leuprolide acetate (LA, Lupron®) administered in single or separate injections in women undergoing *in vitro* fertilization (IVF): Preliminary results. European Society of Reproductive Endocrinology, June 2000.
17. **Montgomery Rice V**, Silverberg KM. "Patient Tolerance to Recombinant Human Follicle Stimulating Hormone (r-hFSH, Gonal-F[R]) and Leuprolide Acetate (LA, Lupron [R]) Administered in Single or Separate Injections in Women Undergoing IVF: Preliminary Results" at American Society for Reproductive Medicine in San Diego, CA, October 21 – 26, 2000.

18. Nothnick WB, **Montgomery Rice V**, Ashwell R. (2001). Endometrial gelatinase and stromelysin activity is elevated in women with endometriosis: Implications into the pathogenesis of the disease. 57th Annual Meeting of the American Society of Reproductive Medicine, October 2001.
19. Consensus working Group, "Management of Women with Chronic Pelvic Pain Secondary to Endometriosis: Development of an Evidence-Based Consensus Approach". Fertility and Sterility (submitted)
20. Richardson MR, Cañez MS, **Montgomery Rice V**, Effects of Metformin on Endocrinologic Parameters of Polycystic Ovarian Syndrome. American Society for Reproductive Medicine, Orlando, FL October 2001

POSTER EXHIBITS:

1. Super ovulation of mice using pure FSH. Soma Weiss Research Presentation, Harvard Medical School Research Forum. Boston, Mass., 1987.
2. FSH induces ovulation of oocytes capable of development to a fetus in the mouse model. American College of Obstetricians and Gynecologists District IV Meeting. North Carolina, 1990.
3. American College of Obstetricians and Gynecologists District IV Meeting - Oral presentation. Prevention of Postoperative adhesion formation using Interceed in the rabbit ovary model. North Carolina, 1990.
4. Poloxamer 407 but not Interceed reduces adhesion formation in the rat uterine horn model. Society of Gynecological Investigation. San Antonio, TX., 1992 .
5. Effects of Poloxamer 407 and ringers lactate on post-operative adhesion formation in the rat uterine horn model. The Second International Symposium on Gynecologic Surgery & Adhesion Prevention. Palm Beach, FL., 1992.
6. The effect of Interceed and Poloxamer 407 on adhesion formation in a rabbit ovarian model. The American Fertility Society, 48th Annual Meeting, New Orleans, LA, 1992.
7. Alteration of the fibrinolytic system in habitual abortion. The American Fertility Society, 48th Annual Meeting, New Orleans, LA, 1992.
8. Intrauterine insemination (IUI): A retrospective comparison of patient pregnancy rates for physician and registered nurse (RN) performed procedures. The American Fertility Society, 48th Annual Meeting, New Orleans, LA., 1992 .
9. Re-epithelization of the rabbit's ovary: Histological Interceed and Poloxamer 407. Society of Gynecological Investigation, 1993.
10. Evidence for hormonally regulated changes in ovarian and circulating levels of bioactive tumor necrosis factor alpha in the gonadotropin-treated immature rat. Society of Gynecological Investigation, Philadelphia PA, March, 1996.
11. Tumor necrosis factor alpha inhibits follicle stimulating hormone-induced granulosa cell estradiol secretion in the human: Dependence on stage of follicular development. Society of Gynecological Investigation, Philadelphia PA, March, 1996.

12. Differential Steroidogenic Responses of Follicles to Tumor Necrosis Factor Alpha in Follicular and Luteal Phases of the Menstrual Cycle. 53rd Annual Meeting of The American Society for Reproductive Medicine, Cincinnati, Ohio, 1997.
13. Poster - Title: (396) "Patient Tolerance to Recombinant Human Follicle Stimulating Hormone (r-hFSH, Gonal-F[R]) and Leuprolide Acetate (LA, Lupron [R]) Administered in Single or Separate Injections in Women Undergoing IVF: Preliminary Results" at American Society for Reproductive Medicine in San Diego, CA, October 21 - 26, 2000.

Ad Hoc Reviewer

American Journal of Obstetrics and Gynecology
Fertility and Sterility
Menopause

Medical Advisory Boards

Medical Advisory Board, Vitality for Life Campaign sponsored by Wyeth-Ayerst
FDA Advisory Board

Miscellaneous Honors

Appointed to the graduate faculty in the Department of Preventive Medicine for the purpose of serving on the thesis committee ~~November 1999~~ November 1999.

**APPEARS THIS WAY
ON ORIGINAL**